SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

July 12, 2012 07:00 ET

Implant Sciences Announces Follow-On Order to Africa for Hotel Security

WILMINGTON, MA--(Marketwire - Jul 12, 2012) - Experiencing growing demand from Africa, Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has sold six more Quantum Sniffer™ QS-H150 handheld explosives trace detectors to a customer in Lagos, Nigeria. The units will be used in screening luggage and cars entering the hotel property.

"We have been increasing our sales to private sector customers across the African continent, including office buildings, industrial facilities, and hotels. The fact that six units are being deployed by one hotel is an indication of the growing demand for security devices in private sector settings and showcases the potential Implant Sciences has to meet the needs of this emerging market," stated Implant Sciences' Vice President of Global Sales and Marketing, Dr. Darryl Jones.

"We expect to see additional sales to Nigeria as well as to the rest of Northern and Sub-Saharan Africa. Because our systems do not use any radioactive materials, they are the desired choice for use in private sector settings. Our sales and distribution teams continue to win contracts due to our Quantum Sniffers' superior performance and technology. These competitive advantages enable us to effectively execute around the globe," added Glenn Bolduc, Implant Sciences' President and CEO.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risk that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by September 30, 2012; that if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; the risk that we continue to incur substantial operating losses and may never be profitable; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; the risk that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact